Cabozantinib added to the kidney cancer treatment arsenal
/Cabozantinib Approval Expands Initial Treatment Options for Advanced Kidney Cancer
For patients with the most common type of kidney cancer, there is now a new approved use of the targeted therapy cabozantinib (Cabometyx®). In December 2017, the Food and Drug Administration (FDA) approved use of the drug as an initial, or first-line, treatment for patients with advanced renal cell carcinoma (RCC).
